Immatics deal adds new mechanism to BMS’s oncology pipeline

BMS takes another step to expand its diversity of therapeutic modalities for immuno-oncology through a deal with Immatics to access a bispecific TCR candidate. 

Immatics N.V. (NASDAQ:IMTV) will receive $150 million up front, up to $770 million in milestones, and tiered double-digit royalties in exchange for rights to IMA401, the biotech’s most advanced TCR bispecific, which targets the MAGEA4/8 solid tumor antigen...